|
Session 173
Poster Abstracts
Hepatitis C Co-infection: Treatment
Tuesday, 1-4 pm
Room: Hall B |
1070
 |
Frequency of RVR and Its Utility as a Predictor of Treatment Outcome In HIV+ and HIV- Individuals with Acute Hepatitis C
Gail Matthews*1, M Hellard2, P Haber3, B Yeung1, D Baker4, A Lloyd5, W Rawlinson6, J Sasadeusz7, J Kaldor1, G Dore1, and on behalf of the ATAHC Study Group
1Natl Ctr for HIV Epidemiology and Clin Res, Univ of New South Wales, Australia; 2Macfarlane Inst for Med Res and Publ Hlth, Melbourne, Australia; 3Drug Hlth Svc, Royal Prince Alfred Hosp, Sydney, Australia; 4407 Doctors, Sydney, Australia; 5Univ of New South Wales, Sch of Med Sci, Sydney, Australia; 6SEALS Microbio, Prince of Wales Hosp, Sydney, Australia; and 7Royal Melbourne Hosp, Australia |
| 1071 |
The TGF-ß High-producer Genotype Is Associated with Response to HCV-specific Therapy in HIV+ Patients with Acute Hepatitis C
Jacob Nattermann*, M Vogel, H Nischalke, G Ahlenstiel, M Michalk, T Sauerbruch, J Rockstroh, U Spengler, and Kompetenznetz HIV/AIDS
Univ of Bonn, Germany |
| 1072 |
High Rate of Sustained Virological Response to an Early Course of Anti-HCV Treatment for Acute HCV Hepatitis in HIV+ Patients
Stephanie Dominguez*1, S Bhagani2, M Vogel3, M Nelson4, J Rockstroh3, E Low4, A Azwa4, M A Valantin1, C Katlama1, and M Guiguet5
1Hosp Pitie-Salpetriere, Paris, France; 2Royal Free Infectious Disease Unit, London, UK; 3Univ of Bonn, Germany; 4Chelsea and Westminster Hosp, London, UK; and 5INSERM U720, Paris VI Univ, Paris, France |
1073
|
On-treatment Responses at Weeks 4 and 12 Can Be Used to Predict Sustained Virological Response Rates in HCV/HIV-co-infected Patients Treated with Peg-Interferonbeta-2a and Ribavirin
M Rodriguez-Torres1, Juergen Rockstroh*2, J Depamphilis3, G Carosi4, D Dieterich5, and F Torriani6
1Fndn de Investigacion de Diego, Santurce, Puerto Rico; 2Univ of Bonn, Germany; 3Roche, Nutley, NJ, US; 4Univ Degli Studi di Brescia, Italy; 5Mt Sinai Sch of Med, New York, NY, US; and 6Univ of California, San Diego, US |
1074
|
Efficacy of Pegylated Interferon + Ribavirin Treatment in HIV/HCV-co-infected Patients Receiving Abacavir + Lamivudine or Tenofovir + either Lamivudine or Emtricitabine as Nucleoside Analogue Backbone
Jose Mira*1, L Lopez-Cortes2, P Barreiro3, C Tural4, M Torres-Tortosa5, I de los Santos Gil6, P Martin-Rico7, M Rios-Villegas8, J Macias1, and J Pineda1
1Hosp Univ de Valme, Seville, Spain; 2Hosp Univ Virgen del Rocio, Seville, Spain; 3Hosp Carlos III, Madrid, Spain; 4Hosp Univ Germans Trias i Pujol, Badalona, Spain; 5Hosp Punta Europa, Algeciras, Spain; 6Hosp Univ de la Princesa, Madrid, Spain; 7Hosp Univ Carlos Haya, Malaga, Spain; and 8Hosp Univ Virgen Macarena, Seville, Spain |
1075
|
Does the Choice of NRTI Have a Significant Influence on the Outcome of peg-IFN plus Ribavirin among HIV/HCV-co-infected Patients?
Ana Moreno*1, C Quereda1, A Muriel2, M Perez-Elias1, J Casado1, F Dronda1, M Mateos3, A Moreno4, R Barcena5, and S Moreno1
1Hosp Ramon y Cajal, Madrid, Spain; 2Hosp Ramon y Cajal, Madrid, Spain; 3Hosp Ramon y Cajal, Madrid, Spain; 4Hosp Ramon y Cajal, Madrid, Spain; and 5Hosp Ramon y Cajal, Madrid, Spain |
1076
|
The Use of TDF+ 3TC/ FTC Is Associated with an Improved Response to Pegylated Interferon + Ribavirin in HIV/HCV-co-infected Patients Receiving HAART: The Gesida 50/06 Study
Juan J Gonzalez-Garcia*1,2, J Berenguer3, E Condes4, C Quereda5, P Labarga6, M Laguno7, M von Wichman8, P Robres9, I Santos10, B Moyano2, and The GESIDA 50/06 Study Group
1Hosp La Paz, Madrid, Spain; 2Agencia de Ensayos Clínicos de Gesida, Spain; 3Hosp Gregorio Maranon, Madrid, Spain; 4Hosp de Mostoles, Madrid, Spain; 5Hosp Ramon y Cajal, Madrid, Spain; 6Hosp Carlos III, Madrid, Spain; 7Hosp Clinic i Provincial, Barcelona, Spain; 8Hosp Donostia, San Sebastian, Spain; 9Hosp de Bellvitge, Barcelona, Spain; and 10Hosp de la Princesa, Madrid, Spain |
1077
|
Race but Not HIV Status Affects Hepatitis C Early Viral Kinetics
Mamta Jain*1, J Shelton1, N Liston1, B Adams-Huet1, N Attar1, H J Yuan1, M Gale2, and W Lee1
1Univ of Texas Southwestern Med Ctr, Dallas, US and 2Univ of Washington, Seattle, US |
1078
|
Treatment Rates and Eligibility in HCV Mono-infected vs HCV/HIV Co-infected Persons
A Butt1,2, J Tsevat3, O Shaikh1, D McMahon1, Uzma Khan*4, Z Dorey-Stein5, and V Lo Re5
1Univ of Pittsburgh Med Ctr, PA, US; 2Ctr for Hlth Equity Res and Promotion, Pittsburgh, PA, US; 3Inst for the Study of Hlth, Univ of Cincinnati Med Ctr and Cincinnati VAMC, OH, US; 4Albany Med Ctr, NY, US; and 5Univ of Pennsylvania Med Ctr, Philadelphia, US |
1079
|
Utility and Predictors of Rapid Viral Response in HCV and HCV/HIV-co-infected Hemophiliacs
Philippe Zamor*1, N Shire1, S Rouster1, E Eyster2, K Sherman1, and Multicenter Hemophilia Cohort HCV Study Group
1Univ of Cincinnati, OH, US and 2Penn State Med Ctr, Hershey, US |
1080
|
Analyzing Substrate Recognition in Terms of Drug Resistance in HCV NS3 Protease
Keith Romano* and C Schiffer
Univ of Massachusetts Med Sch, Worcester, US |
1081a
|
A Novel HCV NS3/4A Protease Assay Using a Bacteriophage Lambda-based Genetic Screen
Sandra Franco*, B Clotet, and M Martinez
irsiCaixa Fndn, Spain |
1081b
|
A Randomized Trial to Compare the Efficacy and Safety of PEG-interferon alfa-2b plus Ribavirin versus PEG-interferon alfa-2a plus Rivabirin for Treatment of Chronic Hepatitis C in HIV Co-infected Patients.
M Laguno1, C Cifuentes2, J Murillas3, F Vidal4, L Bonet3, S Veloso4, C Tural5, I Perez1, J Gatell1, and Josep Mallolas*1
1Hosp Clin Barcelona, Spain; 2Hosp Son Llatzer, Palma de Mallorca, Spain; 3Hosp Son Dureta, Palma de Mallorca, Spain; 4Hosp Joan XXIII, Tarragona, Spain; and 5Hosp Univ Germans Trias i Pujol, Badalona, Spain |
|
